Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer

Clinical Cancer Research

Volumn 11, Issue 13, 2005, Pages 4653-4657

  Titus, Mark A ^a   Schell, Michael J ^a   Lih, Fred B ^b   Tomer, Kenneth B ^b   Mohler, James L ^a,c,d  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANTIANDROGEN; CHOLESTEROL; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN; LEUPRORELIN; LIGAND; TESTOSTERONE;

ADULT; AGED; ANDROGEN BLOOD LEVEL; ANDROGEN SYNTHESIS; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CASTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ELECTROSPRAY MASS SPECTROMETRY; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; SURVIVAL RATE; TISSUE LEVEL; WILCOXON SIGNED RANKS TEST;

AGED; AGED, 80 AND OVER; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIHYDROTESTOSTERONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RADIOIMMUNOASSAY; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SURVIVAL ANALYSIS; TESTOSTERONE;

EID: 27644452640     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-0525     Document Type: Article

References (31)

1. Taplin ME, Balk SP. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 2004;91:483-90.
2. Mohler JL, Gregory CW, Ford OH, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004;10:440-8.
3. Edwards J, Krishna NS, Grigor KM, Bartlett JMS. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003;89:552-6.
4. Linja MJ, Savinainen KJ, Saramäki OR, Tammela TLJ, Vessella RL, Visakorpi T. Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res 2001;61:3550-5.
5. Van der Kwast TH, Schalken J, Ruizeveld de Winter JA, et al. Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 1991;48:189-93.
6. Brown RDS, Edwards J, Dogan A, et al. Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J Pathol 2002;198:237-44.
7. Hobisch A, Culig Z, Radmyr C, Bartsch G, Klocker H, Hittmair A. Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 1995;55:3068-72.
8. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
9. Hobisch A, Hoffmann J, Lambrinidis L, et al. Antagonist/agonist balance of the nonsteroidal antiandrogens bicalutamide (Casodex) in a new prostate cancer model. Urol Int 2000;65:73-9.
10. Gregory CW, He B, Johnson RT, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001;61:4315-9.
11. Tan J-A, Sharief Y, Hamil KG, et al. Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen dependent human prostate cancer xenograft CWR22 and LNCaP cells. Mol Endocrinol 1997;11:450-9.
12. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 2001;1:34-45.
13. Grossman ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen refractory prostate cancer. J Natl Cancer Inst 2001;93:1687-97.
14. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
15. Labrie F. Endocrine therapy for prostate cancer. Endocrinol Metab Clin North Am 1991;20:845-72.
16. Geller J, Albert J, Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 1988;15:53-61.
17. Kliman B, Prout GR Jr, Maclaughlin RA, Daly JJ, Griffin PP. Altered androgen metabolism in metastatic prostate cancer. J Urol 1978;119:623-6.
18. Geller J, Albert J, Loza D. Steroid levels in cancer of the prostate-markers of tumour differentiation and adequacy of anti-androgen therapy. J Steroid Biochem Mol Biol 1979;11:631-6.
19. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-71.
20. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004;10:7121-6.
21. Wang C, Catlin DH, Demers LM, Starcevic B, Swerdloff RS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534-43.
22. Culig Z, Hoffmann J, Erdel M, et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumor progression in a new model system. Br J Cancer 1999;81:242-51.
23. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001;61:2892-8.
24. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5α-reductase isozyme expression. J Clin Invest 1993;92:903-10.
25. Thomas LN, Douglas RC, Vessey JP, et al. 5α-Reductase type 1 immunostaining is enhanced in some prostate cancers compared with benign prostatic hyperplasia epithelium. J Urol 2003;170:2019-25.
26. Titus MA, Gregory CW, OH Ford III, Schell MJ, Maygarden SJ, Mohler JL. Steroid 5α-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005;11:4365-71.
27. Jin Y, Penning TM. Steroid 5-reductases and 3-hydroxysteroid dehydrogenases: key enzymes in androgen metabolism. Best Pract Res Clin Endocrinol Metab 2001;15:79-94.
28. Belanger B, Belanger A, Labrie F, Dupont A, Cusan L, Monfette G. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J Steroid Biochem Mol Biol 1989;32:695-8.
29. Geller J, Albert J, Loza D, Geller S, Stoeltzing W, de la Vega D. DHT concentrations in human prostate cancer tissue. J Clin Endocrinol Metab 1978;46:440-4.
30. Schaffner CP. Prostatic cholesterol metabolism: regulation and alteration. Prog Clin Biol Res 1981;75:279-324.
31. Freeman MR, Solomon KR. Cholesterol and prostate cancer. J Cell Biochem 2004;91:54-69.